Alpha-bloquants

6,7-Dimethoxy-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-4(3H)-quinazolinone is a drug product. It is an analytical standard for the impurity of CAS No. 1177261-73-2. This compound has been synthesized by custom synthesis and its purity is high. The compound has been used in research and development of drugs, pharmacopoeia, HPLC standards, and other related fields.

4-(4-Amino-6-hydroxy-7-methoxy-2-quinazolinyl)-1-piperazinyl](tetrahydro-2-furanyl)-methanone (CAS No. 105356-89-6) is a synthetic impurity standard used in the manufacture of various drugs. Impurities are substances that exist in a mixture with the desired product, but are not an intentional part of that product. Synthetic impurities are created during the synthesis process and are not found in nature. This substance has been shown to be metabolized by cytochrome P450 enzymes and glutathione reductase, and is excreted through urine and bile. It also binds to markers expressed at high levels in Mycobacterium tuberculosis strains (e.g., ESX-1 secretion system protein) and inhibits cell growth in culture.

Alfuzosin (SL 77499) is an alpha-1 adrenergic antagonist used to treat benign prostatic hypertrophy and urethral dysfunction.

Labetalol hydrochloride (Sch-15719W), a salicylamide derivative, is a non-cardioselective blocker of β-adrenergic receptors and α1-adrenergic receptors.

Alfuzosin is a drug used to treat the signs and symptoms of benign prostatic hyperplasia (BPH). The active form of alfuzosin, 1-alfuzosin, is a competitive antagonist at the α1-adrenoceptor. Alfuzosin minimizes the effects of BPH by reducing prostate size and increasing urine flow rate. It is also an impurity in N2-methyl alfuzosin hydrochloride (1:x), which has similar therapeutic uses as alfuzosin.

Aromatic cyclic amides (including cyclic carbamates) and their derivatives; salts thereof